leisure time -WSS

leisure time

author：fashion 2025-09-03 05:41:42 - browse：4

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Senate panel puts off hardest PBM reforms for another day

knowledge

focus

WSS

The battle over 'scope creep' and who gets to be called 'doctor'

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

UHS says company favors patients whose insurance pays more

How doctors’ personal politics affect patients

Hospital at home shows how to bring innovation to health care

Biogen says it will cut costs by $700 million, slash 1,000 jobs

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

How to save PrEP access — and even expand it

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

ChatGPT in medicine: STAT answers readers' burning questions

Former Pear Therapeutics executives start new VC firm

Hollywood unions extend contract negotiations for actors

How the drug

Dobbs anniversary: the lost opportunity of abortion as health care

Dems pitch expanding Medicare power to negotiate drug prices

Medicare proposal to cover medical devices draws a mixed reaction

As obesity drug market grows, telehealth companies court payers

focus

People can get long Covid without testing positive for virus: Study

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Hospital at home shows how to bring innovation to health care

Democrats decry new health bill for going easy on private equity

Abortion policy in the spotlight at Republican debate

Abortion policy in the spotlight at Republican debate

entertainment

knowledge

focus

knowledge